Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial

Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial

Summary: Background: The effectiveness of combination therapy for COVID-19 pneumonia remains unclear. We evaluated favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia. Methods: In this open-label phase 3 study, hospitalized adults who were positiv...

Full description

Bibliographic Details
Main Authors:	Jiro Terada, Retsu Fujita, Takuya Kawahara, Yasutaka Hirasawa, Taku Kinoshita, Yuichiro Takeshita, Yuri Isaka, Toru Kinouchi, Hiroshi Tajima, Yuji Tada, Kenji Tsushima
Format:	Article
Language:	English
Published:	Elsevier 2022-07-01
Series:	EClinicalMedicine
Subjects:	COVID-19 Camostat Ciclesonide Combination therapy Favipiravir Hospital stay
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537022002140

Similar Items

COVID‐19 pneumonia suspected to be co‐infection with Mycoplasma pneumoniae and improved by early administration of favipiravir and ciclesonide
by: Keima Ito, et al.
Published: (2021-09-01)

Control of moderate-to-severe asthma with randomized ciclesonide doses of 160, 320 and 640 μg/day
by: Pedersen SE, et al.
Published: (2017-03-01)

Inhaled ciclesonide for outpatients with COVID-19: A meta-analysis
by: Chi-Kuei Hsu, et al.
Published: (2022-12-01)

Ciclesonide activates glucocorticoid signaling in neonatal rat lung but does not trigger adverse effects in the cortex and cerebellum
by: Juliann D. Jaumotte, et al.
Published: (2021-08-01)

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19
by: Yuri Kosinsky, et al.
Published: (2022-04-01)

The Effectiveness and Safety of Ciclesonide versus Fluticasone, Budesonide, and Beclomethasone in Treatment of Persistent Asthma: A Comprehensive Review of Literature
by: Zahra Zali, et al.
Published: (2014-05-01)

Favipiravir in Therapy of Viral Infections
by: Ryta Łagocka, et al.
Published: (2021-01-01)

Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication
by: Genichiro Tsuji, et al.
Published: (2022-07-01)

The Antiasthma Medication Ciclesonide Suppresses Breast Cancer Stem Cells through Inhibition of the Glucocorticoid Receptor Signaling-Dependent YAP Pathway
by: Su-Lim Kim, et al.
Published: (2020-12-01)

A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats
by: Teruhiko Mizumoto, et al.
Published: (2021-08-01)

A Serine Protease Inhibitor, Camostat Mesilate, Suppresses Urinary Plasmin Activity and Alleviates Hypertension and Podocyte Injury in Dahl Salt-Sensitive Rats
by: Yasunobu Iwata, et al.
Published: (2023-10-01)

Camostat mesilate, a serine protease inhibitor, exerts aquaretic effects and decreases urinary exosomal AQP2 levels
by: Yutaka Kakizoe, et al.
Published: (2022-12-01)

Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study
by: Gwanyoung Kim, et al.
Published: (2023-09-01)

Repeated-Dose Pharmacokinetics of Inhaled Ciclesonide (CIC-HFA) in Japanese Children with Bronchial Asthma: A Phase I Study
by: Takahide Teramoto, et al.
Published: (2012-01-01)

A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
by: Taku Kinoshita, et al.
Published: (2022-09-01)

Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases
by: Akmaral Assylbekova, et al.
Published: (2022-04-01)

Camostat mesilate inhibits pro-inflammatory cytokine secretion and improves cell viability by regulating MFGE8 and HMGN1 in lipopolysaccharide-stimulated DF-1 chicken embryo fibroblasts
by: Lin Yuan, et al.
Published: (2021-08-01)

Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study
by: Kuan-Chih Kuo, et al.
Published: (2022-09-01)

Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19
by: Tanuj Sharma, et al.
Published: (2022-03-01)

Inhibitory potentials of ivermectin, nafamostat, and camostat on spike protein and some nonstructural proteins of SARS-CoV-2: Virtual screening approach
by: Haruna Isiyaku Umar, et al.
Published: (2022-06-01)

Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks
by: Hanan M. El-Laithy, et al.
Published: (2021-01-01)

The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b
by: Yue-Zhi Lee, et al.
Published: (2022-07-01)

Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial
by: Joon-Young Song, et al.
Published: (2021-08-01)

Ciclesonide in the treatment of patients with bronchial asthma
by: V. I. Trofimov
Published: (2014-12-01)

Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial
by: Els Tobback, et al.
Published: (2022-09-01)

A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC)
by: Mitchell L. Ramsey, et al.
Published: (2019-08-01)

Effect of favipiravir and an anti-inflammatory strategy for COVID-19
by: Hitoshi Yamamura, et al.
Published: (2020-07-01)

Hematological Malignancy Patients, COVID-19, and Favipiravir
by: Rujittika Mungmunpuntipantip, et al.
Published: (2021-12-01)

Potential of Favipiravir and Minocycline Combination Therapy for COVID-19
by: Kazuhiro Itoh, et al.
Published: (2022-01-01)

Evaluation of the effect of favipiravir on patients with COVID-19
by: Alireza Kamali, et al.
Published: (2023-01-01)

Follow-up of Favipiravir-Induced Nail Fluorescence: Implications for Nail and Drugs
by: Hüsna Güder, et al.
Published: (2023-01-01)

Favipiravir: the hidden threat of mutagenic action
by: O. P. Zhirnov, et al.
Published: (2021-05-01)

Favipiravir Use in COVID-19 Treatment
by: Emre KARA, et al.
Published: (2021-03-01)

SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion
by: Sarah Halford, et al.
Published: (2021-08-01)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
by: Rahmet Guner, et al.
Published: (2021-03-01)

Favipiravir Inhibits Mayaro Virus Infection in Mice
by: Michèle Bengue, et al.
Published: (2021-11-01)

Three-step process for the synthesis of favipiravir
by: Swarnayu Banik, et al.
Published: (2023-01-01)

Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus
by: Jennifer Mayor, et al.
Published: (2021-06-01)

A case report of urticaria as a rare side effect of favipiravir in a patient with COVID-19
by: Amit Kumar, et al.
Published: (2021-01-01)

Does Favipiravir Reduce Mortality in Patients with COVID-19 ARDS and Severe Pneumonia?
by: Khin Zar Li Aung, et al.
Published: (2021-12-01)